Astrazeneca Pharma India Ltd.
Fundamentals
- Market cap
- ₹20,978 cr
- P/E
- 111.87×
- ROE
- 15.02%
- Debt / equity
- 0.00
- Div yield
- 0.43%
- 52-week range
- 7551.50 — 9849.50
Astrazeneca Pharma India Ltd.
Latest quarter · Mar 2026
Strength & growth
The timeline — 6 notes on Astrazeneca Pharma India Ltd.
July 2026
- 28 Jul 26 · 1:24 PM IST Lead Lead · Regulatory · Large cap
AstraZeneca India gets Enhertu nod for early-stage breast cancer
The drug regulator cleared neoadjuvant use in HER2-positive Stage II/III breast cancer, expanding the addressable pool for the company's top oncology product, which already drove over ₹22,756 mn in FY26 revenue.
- 16 Jul 26 · 2:27 PM IST Lead Lead · Large cap
AstraZeneca India gets CDSCO nod for Fasenra in rare hypereosinophilic syndrome
The approval expands the drug's use beyond severe asthma, but the patient pool for this rare disease is small. Financial impact is likely modest relative to recent oncology wins.
May 2026
- 26 May 26 · 7:50 PM IST Brief Brief · Earnings · Large cap
AstraZeneca Pharma India revenue climbs 33% on oncology drug launches
The company posted a net profit of ₹1.9 billion for FY26, supported by 11 new regulatory approvals and a dividend recommendation of ₹36 per share.
- 26 May 26 · 7:17 PM IST Brief Brief · Earnings · Large cap
AstraZeneca Pharma India profit rises to ₹1.9 billion
Revenue hit ₹22.8 billion for FY26 as oncology sales grew. The board recommended a final dividend of ₹36 per share.
- 21 May 26 · 1:27 PM IST Lead Lead · Large cap
AstraZeneca India wins CDSCO nod for Calquence in MCL
Second Indian approval for BTK inhibitor after CLL; broadens addressable patient pool in aggressive lymphoma.